KEGG   DRUG: Sipavibart
Entry
D12974                      Drug                                   
Name
Sipavibart (INN);
Sipavibart (genetical recombination) (JAN);
Kavigale (TN)
Formula
C6430H9880N1704O2022S40
Exact mass
144599.1496
Mol weight
144688.12
Sequence
(Heavy chain)
EVQLVESGGG LVQPGRSLRL SCAASGFPFD DYAIHWVRLA PGKGLEWVSS ISWDSGSIGY
ADSVKGRFTI SRDNAKNSLY LQMNSLRAED TALYYCAKGA FPGYSSGWYY GLEVWGQGTT
VTVSSASTKG PSVFPLAPSS KSTSGGTAAL GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA
VLQSSGLYSL SSVVTVPSSS LGTQTYICNV NHKPSNTKVD KRVEPKSCDK THTCPPCPAP
EFEGGPSVFL FPPKPKDTLY ITREPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR
EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK VSNKALPASI EKTISKAKGQ PREPQVYTLP
PSREEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFFLYSKLTV
DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK
(Light chain)
QSVVTQPPSA SGSLGQSVTI SCTGTSSDVG GYNYVSWYQQ HPGKAPKLMI FEVSKRPSGV
PDRFSGSKSG NTASLTVSGL QAEDEADYYC SSYAGNKGVF GGGTKLTVLG QPKAAPSVTL
FPPSSEELQA NKATLVCLIS DFYPGAVTVA WKADSSPVKA GVETTTPSKQ SNNKYAASSY
LSLTPEQWKS HRSYSCQVTH EGSTVEKTVA PTECS
(Disulfide bridge: H22-H96, H152-H208, H228-L214, H234-H'234, H237-H'237, H269-H329, H375-H433, H'22-H'96, H'152-H'208, H'228-L'214, H'269-H'329, H'375-H'433, L22-L90, L137-L196, L'22-L'90, L'137-L'196)
  Type
Peptide
Class
Antiviral
 DG03174  Anti-SARS-CoV-2 agent
Remark
Therapeutic category: 6250
ATC code: J06BD09
Product: D12974<JP>
Efficacy
Antiviral
  Type
Monoclonal antibody
Comment
Treatment of severe acute respiratory syndrome (SARS) and COVID-19
Target
SARS-CoV-2 spike glycoprotein [KO:K24152]
  Pathway
ko03230  Viral genome structure
ko03262  Virion - Coronavirus
ko05171  Coronavirus disease - COVID-19
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J06 IMMUNE SERA AND IMMUNOGLOBULINS
   J06B IMMUNOGLOBULINS
    J06BD Antiviral monoclonal antibodies
     J06BD09 Sipavibart
      D12974  Sipavibart (INN) <JP>
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  62  Chemotherapeutics
   625  Antivirals
    6250  Antivirals
     D12974  Sipavibart (INN); Sipavibart (genetical recombination) (JAN)
Drug groups [BR:br08330]
 Antiviral
  DG03174  Anti-SARS-CoV-2 agent
   D12974  Sipavibart
Antimicrobials [BR:br08307]
 Antivirals
  Entry, fusion or uncoating inhibitor
   Coronavirus spike protein
    D12974  Sipavibart (INN) <JP>
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D12974
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D12974
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D12974
Other DBs
CAS: 2768288-97-5
PubChem: 504099490
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system